CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 5.63 HKD -2.09% Market Closed
Market Cap: 8.2B HKD

Wall Street
Price Targets

Price Targets Summary
CStone Pharmaceuticals

Wall Street analysts forecast CStone Pharmaceuticals stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CStone Pharmaceuticals is 13.93 HKD with a low forecast of 7.38 HKD and a high forecast of 21 HKD.

Lowest
Price Target
7.38 HKD
31% Upside
Average
Price Target
13.93 HKD
147% Upside
Highest
Price Target
21 HKD
273% Upside
CStone Pharmaceuticals Competitors:
Price Targets
JSPR
Jasper Therapeutics Inc
631% Upside
ALDX
Aldeyra Therapeutics Inc
99% Upside
9926
Akeso Inc
57% Upside
DAWN
Day One Biopharmaceuticals Inc
156% Upside
CYTK
Cytokinetics Inc
20% Upside
300896
Imeik Technology Development Co Ltd
29% Upside

Revenue
Forecast

Revenue Estimate
CStone Pharmaceuticals

The compound annual growth rate of CStone Pharmaceuticals's revenue for the next 3 years is 20%.

N/A
Past Growth
20%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CStone Pharmaceuticals

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
17%
Average Beat

Net Income
Forecast

Net Income Estimate
CStone Pharmaceuticals

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CStone Pharmaceuticals's stock price target?
Price Target
13.93 HKD

According to Wall Street analysts, the average 1-year price target for CStone Pharmaceuticals is 13.93 HKD with a low forecast of 7.38 HKD and a high forecast of 21 HKD.

What is CStone Pharmaceuticals's Revenue forecast?
Projected CAGR
20%

The compound annual growth rate of CStone Pharmaceuticals's revenue for the next 3 years is 20%.

Back to Top